6-Phosphogluconate is a six-carbon sugar acid that sits at a critical junction in the pentose phosphate pathway, one of the oldest and most conserved metabolic routes in biology. Its importance stems from what happens to it: the enzyme 6-phosphogluconate dehydrogenase (6PGD) converts it into ribulose 5-phosphate while generating NADPH, a molecule cells depend on for antioxidant defense and biosynthesis. But 6-phosphogluconate does more than simply pass through a reaction. It also acts as a regulatory signal, influencing how much glucose flows through competing metabolic routes, and its handling enzyme has become a target of intense interest in cancer research and drug development.
Where 6-Phosphogluconate Fits in Cellular Metabolism
Cells break down glucose through several routes, and the pentose phosphate pathway (PPP) is one of the most important alternatives to straightforward glycolysis. The oxidative branch of the PPP runs three sequential reactions, each catalyzed by a different enzyme. The first, glucose-6-phosphate dehydrogenase (G6PDH), oxidizes glucose 6-phosphate and produces the first molecule of NADPH. The second enzyme, 6-phosphogluconolactonase, hydrolyzes the resulting lactone into 6-phosphogluconate. The third enzyme, 6-phosphogluconate dehydrogenase (6PGD), then oxidizes 6-phosphogluconate while generating a second molecule of NADPH and releasing carbon dioxide, yielding ribulose 5-phosphate as its product.1PubMed. The enzymes of the oxidative phase of the pentose phosphate pathway as targets of reactive species: consequences for NADPH production Both the first and third steps are the NADPH-producing reactions, making them the primary reason cells run this pathway at all.
NADPH is the cell’s main reducing currency for detoxification and biosynthesis. It regenerates glutathione, the principal antioxidant that neutralizes reactive oxygen species, and it provides the electrons needed to build fatty acids, cholesterol, and nucleotides.2PubMed Central. Antioxidant SMe1EC2 modulates pentose phosphate pathway and glutathione-dependent enzyme activities in tissues of aged diabetic rats The other product, ribulose 5-phosphate, feeds into the non-oxidative branch of the pathway, where it can be rearranged into ribose 5-phosphate for DNA and RNA synthesis, or shuffled back into glycolytic intermediates depending on what the cell needs.
How 6-Phosphogluconate Is Formed
The immediate precursor to 6-phosphogluconate is 6-phosphogluconolactone, a cyclic ester produced by the first enzyme of the oxidative PPP. In most organisms, the enzyme 6-phosphogluconolactonase (Pgl) catalyzes the hydrolysis of this lactone ring, opening it to produce 6-phosphogluconate. This step seems simple, and for a long time researchers treated it as almost trivial because the lactone can also open spontaneously in water without any enzyme at all. Recent work, however, suggests that Pgl is more important than it looks: without it, the spontaneous hydrolysis is slow enough to reduce the overall flux through the pathway.3FEBS J / Wiley Online Library. 6-Phosphogluconolactonase is critical for the efficient functioning of the pentose phosphate pathway In cells that need to run the PPP at high speed, relying on spontaneous hydrolysis alone would create a bottleneck.
What Happens When 6PGD Acts on It
The reaction catalyzed by 6-phosphogluconate dehydrogenase is a textbook example of oxidative decarboxylation, but the details of how the enzyme actually pulls it off are surprisingly intricate. Computational and experimental studies have converged on a three-step mechanism. First, 6-phosphogluconate transfers a hydride to the cofactor NADP⁺ while simultaneously losing a proton from its 3-hydroxyl group to a lysine residue in the active site, forming a 3-keto intermediate. Second, carbon dioxide is released from that intermediate, again with a proton shuttle back from the same lysine. Third, a double proton transfer involving a glutamate residue yields the final product, the keto form of ribulose 5-phosphate.4PubMed. Catalytic mechanism of 6-phosphogluconate dehydrogenase: a theoretical investigation The slowest of these three steps is the first one, making the initial hydride transfer the rate-limiting event.5PubMed. Chemical mechanism of 6-phosphogluconate dehydrogenase from Candida utilis from pH studies
Crystal structures of the enzyme show that the active site is a deep cleft formed by residues from all three structural domains of the protein, with the 6-phosphate group of the substrate anchored by a network of ionic and hydrogen-bonding interactions involving conserved tyrosine, lysine, threonine, and arginine residues.6PubMed. Importance in catalysis of the 6-phosphate-binding site of 6-phosphogluconate in sheep liver 6-phosphogluconate dehydrogenase These phosphate-binding interactions do more than just hold the substrate in place. They orient 6-phosphogluconate correctly for catalysis and trigger a conformational change that primes the active site for the reaction.7PubMed Central. Crystal structures of a bacterial 6-phosphogluconate dehydrogenase reveal aspects of specificity, mechanism and mode of inhibition by analogues of high-energy reaction intermediates The enzyme functions as a dimer, with the tail domain of one subunit contributing residues to the active site of its partner, meaning the two subunits depend on each other for full catalytic activity.
6-Phosphogluconate as a Metabolic Traffic Signal
Beyond being a simple intermediate that gets consumed and passed along, 6-phosphogluconate has a regulatory role that is easy to overlook. It is a potent inhibitor of phosphoglucose isomerase (PGI), the enzyme that converts glucose 6-phosphate into fructose 6-phosphate at the entry point of glycolysis. This inhibition is competitive and remarkably strong. In rat brain tissue, 6-phosphogluconate inhibited PGI with an inhibition constant around 0.04 to 0.05 mM, and at concentrations of 0.5 to 2.0 mM it shut the enzyme down completely when glucose 6-phosphate was the substrate.8PubMed. Effect of 6-phosphogluconate on phosphoglucose isomerase in rat brain in vitro and in vivo
The practical implication is that when 6-phosphogluconate builds up, it slows glycolysis and pushes more glucose 6-phosphate toward the pentose phosphate pathway instead. This creates a feedback loop: the more the PPP is active, the more 6-phosphogluconate accumulates, and the more glucose gets diverted into the PPP rather than being burned for energy through glycolysis.9Nature. Inhibition of Phosphoglucose Isomerase The cell effectively uses 6-phosphogluconate concentration as a dial to partition glucose between energy production and the biosynthetic and antioxidant functions served by the PPP. In tissues with high oxidative stress or rapid growth, where NADPH demand is elevated, this feedback mechanism becomes especially relevant.
Cancer Cells Exploit 6PGD
Cancer cells are metabolic opportunists, and the enzyme that handles 6-phosphogluconate has turned out to be one of their favorite tools. Elevated 6PGD activity has been reported across many tumor types, including colorectal cancers, cervical neoplasia, thyroid tumors, and breast cancer, where it has been documented as a prognostic biomarker.10Molecular Cell. Lysine Acetylation Activates 6-Phosphogluconate Dehydrogenase to Promote Tumor Growth One mechanism behind this activation involves lysine acetylation: cancer cells add acetyl groups to two specific lysine residues on 6PGD, boosting its activity and helping coordinate the anabolic biosynthesis, redox balance, and glycolytic rewiring that tumor cells need to keep dividing.
Suppressing 6PGD in cancer cells has measurable consequences. Experiments show that blocking the enzyme reduces fat production and RNA biosynthesis while increasing reactive oxygen species, all of which slow tumor growth. Researchers have identified small-molecule inhibitors, including physcion and its derivative S3, that block 6PGD and inhibit tumor growth in mouse models without obvious toxicity.11PubMed Central. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling More recent work has expanded the search for 6PGD inhibitors to natural-product libraries, identifying lignan compounds as lead candidates for lung cancer therapy.12PubMed Central. Identification of Lignan Compounds as New 6-Phosphogluconate Dehydrogenase Inhibitors for Lung Cancer
In breast cancer specifically, 6PGD inhibition activates the AMPK energy-sensing pathway, which puts the brakes on cell growth. This has led to the suggestion that targeting 6PGD could complement existing chemotherapy regimens rather than replace them.13PubMed. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation The connection between 6PGD and the ER (endoplasmic reticulum) adds another dimension: when 6PGD is suppressed, glutathione levels drop and the ER’s structure dilates, disrupting protein secretion. Boosting glutathione synthesis separately can rescue ER integrity even when 6PGD is inhibited, suggesting the ER damage is driven specifically by the loss of reducing power rather than by the loss of pentose sugars.14Cell Chemical Biology. PGD-Mediated Carbohydrate Metabolism Supports Protein Secretion and ER Structural Integrity
What Happens When 6PGD Is Deficient in Humans
Genetic deficiency of 6PGD is extremely rare, but the handful of documented cases are informative. A Spanish family with about 50% of normal 6PGD activity showed a split phenotype: two female members had chronic hemolytic anemia (ongoing destruction of red blood cells), while two other family members with the same enzyme deficiency had no symptoms at all.15American Journal of Hematology. Congenital 6-phosphogluconate dehydrogenase (6PGD) deficiency associated with chronic hemolytic anemia in a Spanish family The symptomatic members had unstable red blood cell glutathione and dramatically increased levels of certain glycolytic intermediates, with fructose 1,6-bisphosphate elevated roughly 50-fold. This metabolic chaos appears to stem from the red cells’ inability to handle oxidative stress, which then spills over to disrupt glycolysis.
A similar pattern appeared in an Italian family, where one affected individual had recurrent jaundice from episodic hemolysis, while her mother, carrying the same deficiency, was clinically fine.16PubMed. 6-Phosphogluconate dehydrogenase deficiency in an Italian family These cases echo what is well known about the more common G6PDH deficiency: red blood cells are uniquely vulnerable because they lack mitochondria and rely entirely on the PPP for NADPH. When any step in that pathway falters, red cells lose their antioxidant shield and become prone to destruction, especially during infections or exposure to oxidizing drugs.
6-Phosphogluconate in Infectious Disease
The dependence of rapidly dividing cells on 6PGD is not limited to cancer. The malaria parasite Plasmodium falciparum faces enormous oxidative stress inside the red blood cell it invades, and it relies heavily on NADPH generated by the PPP for antioxidant defense while simultaneously needing ribose 5-phosphate to fuel its rapid DNA and RNA synthesis. This makes the parasite’s 6PGD an appealing antimalarial drug target, distinct from the human host’s version of the enzyme.17PubMed. Characterization of Plasmodium falciparum 6-Phosphogluconate Dehydrogenase as an Antimalarial Drug Target Structural differences between the parasite and human enzymes make selective inhibition plausible, though no antimalarial 6PGD inhibitor has reached clinical trials yet.
Some bacteria use 6-phosphogluconate differently. In the Entner-Doudoroff pathway, which certain bacteria employ as an alternative to standard glycolysis, 6-phosphogluconate is dehydrated rather than decarboxylated. The bacterium Helicobacter pylori, for instance, uses 6-phosphogluconate dehydratase to strip water from the molecule, eventually splitting it into pyruvate and glyceraldehyde 3-phosphate through a completely different route than the PPP uses.18Archives of Biochemistry and Biophysics. The Entner-Doudoroff Pathway in Helicobacter pylori The same molecule, 6-phosphogluconate, can thus have a fundamentally different metabolic fate depending on which organism is handling it.
6-Phosphogluconate in Plants and Grain Development
Plants maintain duplicate copies of many PPP enzymes, with one set in the cytoplasm and another inside the chloroplast (or, in non-photosynthetic tissues, the amyloplast). In maize, the chloroplast-localized version of 6PGD turns out to be essential for starch accumulation in the kernel. Loss-of-function mutations in the gene encoding this enzyme, called pgd3, produce rough, shrunken kernels with reduced starch and embryo oil.19PubMed Central. Chloroplast-localized 6-phosphogluconate dehydrogenase is critical for maize endosperm starch accumulation Isotope-labeling experiments confirmed that carbon flux into starch is altered in these mutants, while losing the cytoplasmic version of 6PGD had no such effect. The plastid-localized enzyme appears to supply the NADPH and pentose precursors that the starch synthesis machinery inside the amyloplast depends on. For crop scientists, this finding highlights that the two copies of 6PGD are not interchangeable, and that engineering one without considering the other could have unintended effects on grain quality.
Tracing PPP Flux Through the 6-Phosphogluconate Node
Because 6-phosphogluconate sits at the branch point between several competing metabolic routes, measuring how much carbon flows through it can reveal a great deal about a cell’s metabolic state. One approach uses isotope-labeled gluconate fed alongside unlabeled glucose. Because gluconate enters the PPP directly as 6-phosphogluconate, any labeled carbon detected in downstream metabolites must have passed through the 6PGD reaction. By measuring the pattern of labeled carbons in those downstream products, researchers can calculate the PPP split ratio, the fraction of glucose that a cell diverts into the pentose phosphate pathway rather than glycolysis.20PubMed Central. 13C-labeled gluconate tracing as a direct and accurate method for determining the pentose phosphate pathway split ratio in Penicillium chrysogenum
Similar isotope-tracing methods have been applied to parasites like Trypanosoma brucei, which causes sleeping sickness. Feeding the parasite uniformly labeled glucose showed that PPP intermediates including 6-phosphogluconate and ribose 5-phosphate were fully labeled, confirming that the oxidative PPP derived directly from glucose 6-phosphate is the parasite’s major source of ribose for nucleotide synthesis.21PLOS Pathogens. Probing the Metabolic Network in Bloodstream-Form Trypanosoma brucei Using Untargeted Metabolomics with Stable Isotope Labelled Glucose These techniques are valuable not only for basic research but also for identifying metabolic vulnerabilities in pathogens and tumor cells that might be exploited therapeutically.
Immune Cells and the PPP Connection
Macrophages, the immune cells that engulf pathogens and drive inflammation, rely on the pentose phosphate pathway to fuel their inflammatory response. When macrophages are activated by bacterial signals, they ramp up the PPP to produce the NADPH needed for generating reactive oxygen species that kill invaders. Suppressing the PPP in macrophages diminishes their ability to secrete inflammatory signaling molecules in response to bacterial lipopolysaccharide.22PubMed. A Defective Pentose Phosphate Pathway Reduces Inflammatory Macrophage Responses during Hypercholesterolemia This finding has implications for chronic inflammatory conditions: in diseases characterized by excessive macrophage activation, the PPP and by extension the 6-phosphogluconate node could represent a point of intervention, though translating that idea into a therapy without crippling the immune system’s legitimate defense functions would be a delicate balancing act.
Neurodegenerative Disease and PPP Disruption
The brain is metabolically demanding and acutely sensitive to oxidative damage, so disruptions in the PPP can have outsized consequences there. In a mouse model of amyotrophic lateral sclerosis (ALS), the spinal cord showed a roughly 37% reduction in ribose 5-phosphate levels and a 24% decrease in glucose-6-phosphate dehydrogenase activity at the early symptomatic stage of disease, pointing to a broadly impaired PPP.23SpringerLink / Molecular Neurobiology. Impaired Pentose Phosphate Pathway in the Spinal Cord of the hSOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis Although this study measured the first enzyme of the oxidative PPP rather than 6PGD directly, a reduction at the G6PDH step would reduce the supply of 6-phosphogluconate downstream, starving 6PGD of its substrate and limiting the second NADPH-producing reaction as well. The result is diminished antioxidant capacity at exactly the moment when motor neurons are under escalating oxidative attack.
Metabolic Engineering and Industrial Applications
6PGD’s cofactor preference has attracted attention from biotechnologists trying to rewire yeast metabolism. In standard baker’s yeast (Saccharomyces cerevisiae), the native 6PGD uses NADP⁺ as its cofactor. Replacing it with a bacterial version that prefers NAD⁺ shifted the cell’s redox balance, increasing cytoplasmic NADH production. In anaerobic fermentation, this swap raised glycerol yield on glucose by roughly 15%, reflecting the extra NADH the cell was now producing and had to dispose of.24PubMed Central. Improving ethanol yield in acetate-reducing Saccharomyces cerevisiae by cofactor engineering of 6-phosphogluconate dehydrogenase and deletion of ALD6 While higher glycerol yield is usually undesirable in ethanol production (it diverts carbon away from ethanol), the broader strategy of cofactor engineering at the 6PGD step demonstrates how intimately this single enzyme node influences the entire redox economy of the cell. For industrial fermentation, this kind of precise enzyme swapping offers a way to fine-tune product yields without overhauling entire pathways.